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Klotho is a renal protein involved in phosphate homeostasis, which is down-regulated in renal 
disease. It has long been considered an anti-ageing factor. Two Klotho gene transcripts are 
thought to encode membrane-bound and secreted Klotho. Indeed, soluble Klotho is detectable in 
bodily fluids, but the relative contributions of Klotho secretion and of membrane-bound Klotho 
shedding are unknown. Recent advances in RNA surveillance reveal that premature termination 
codons, as present in alternative Klotho mRNA (for secreted Klotho), prime mRNAs for 
degradation by nonsense-mediated mRNA decay (NMD). Disruption of NMD led to 
accumulation of alternative Klotho mRNA, indicative of normally continuous degradation. RNA 
immunoprecipitation for NMD core factor UPF1 resulted in enrichment for alternative Klotho 
mRNA, which was also not associated with polysomes, indicating no active protein translation. 
Alternative Klotho mRNA transcripts co-localized with some P bodies, where NMD transcripts 
are degraded. Moreover, we could not detect secreted Klotho in vitro. These results suggest that 
soluble Klotho is likely cleaved membrane-bound Klotho only. Furthermore, we found that 
especially in acute kidney injury, splicing of the two mRNA transcripts is dysregulated, which 
was recapitulated by various noxious stimuli in vitro. This likely constitutes a novel mechanism 







Deficiency of Klotho (sometimes denoted as αKlotho) shortens lifespan and leads to a phenotype 
resembling human ageing (1), whereas overexpression of Klotho extends lifespan by 20-30% (2) 
and protects against the development of many pathological phenotypes, particularly renal disease 
(3-7). Klotho is therefore considered a potential target for treatment of renal and ageing-related 
diseases. The Klotho gene contains 5 exons and the corresponding membrane-bound Klotho 
protein is predominantly expressed in the kidney (8). This membrane-bound protein functions as 
a co-receptor to fibroblast growth factor (FGF) receptor 1c, enabling FGF23 signaling and 
promoting phosphaturia(9-11). Membrane-bound Klotho expression is dramatically reduced in 
patients with chronic kidney disease (CKD), which due to end-organ resistance fosters an early 
rise in FGF23 levels and a later rise in serum phosphate(12). Membrane-bound Klotho is 
proteolytically cleaved into soluble Klotho proteins, which may be the Klotho proteins chiefly 
responsible for exerting systemic beneficial effects after shedding to blood, urine, or 
cerebrospinal fluid (13,14). However, alternative splicing also generates an alternative mRNA 
transcript, assumed since its discovery in 1998 to code for a secreted Klotho protein(8). In this 
transcript, 50 nucleotides of intronic sequence after exon 3 are followed by a premature 
termination codon (PTC), precluding translation of (downstream) exon 5 encoding the 
transmembrane domain (8), leading to the long-standing assumption that the resultant protein is 
secreted. While the existence of this alternative transcript is well-documented (15-18), the 
existence of this putative secreted Klotho protein has never been demonstrated, nor has the 
process of Klotho secretion. The only study to date to specifically address this issue found that 
any putative secreted Klotho protein smaller than the full-length 130 kDa soluble Klotho could 
 3 
 
not be detected in human serum or CSF(13). Mice also express an alternative Klotho mRNA 
(15,16,19-22), a protein of which is also yet to be found in blood, however (13,23). Rats, though, 
have only been found to express membrane-bound Klotho mRNA (24), which intuitively 
undercuts a supposed conserved role for secreted Klotho in physiology. 
Recent advances in RNA surveillance mechanisms indicate that mRNA transcripts with PTCs 
are targets for nonsense-mediated mRNA decay (NMD). Although different models for NMD 
triggers are yet to be unified, the presence of a PTC >50 nucleotides upstream of an exon-exon 
junction and with a sufficiently large distance to the poly(A) tail constitutes a well-characterized, 
potent initiator for NMD. UPF1 (up-frameshift protein 1), an NMD core factor, binds to the 3’ 
UTR of all mRNA molecules and is displaced by the ribosome during the pioneer round of 
translation (25). If not displaced, as occurs when a PTC is encountered, UPF1 is phosphorylated, 
subsequently recruiting factors that initiate degradation of the aberrant mRNA (26). The human 
alternative Klotho mRNA transcript has been coined as a possible NMD candidate (27), although 
this has not yet been substantiated by evidence. Murine klotho mRNAs were shown to be 
susceptible to NMD after introduction of a PTC in exon 1, adding credence to the possibility that 
a human PTC-containing Klotho mRNA may also be an NMD target (28). 
Not only is Klotho expression especially decreased in renal disease (29,30), maintained or 
elevated Klotho expression levels have been demonstrated to have substantial renoprotective 
effects (3,7,31). The kidney is also the principal source of Klotho (32). Given the pleiotropic and 
profound effects of soluble Klotho proteins, it is of great importance to determine the structures 
of soluble Klotho proteins and the structure-function relationships between soluble Klotho and 
the molecules with which Klotho interacts. Furthermore, of particular importance are the 
mechanisms of shedding and/or secretion of Klotho, which could be targeted as a treatment 
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strategy to up-regulate Klotho levels. In this study, we aimed to determine whether the 
alternative Klotho mRNA transcript is an NMD target mRNA, and whether this has any 






Detection of membrane-bound and alternative Klotho mRNA transcripts 
We confirmed the expression of both membrane-bound and alternative Klotho mRNA transcripts 
in human kidney, primary human renal tubular epithelial cells (RTECs), and a human renal 
epithelial cell line (HK-2) using RT-PCR. Using primers that amplify both alternative Klotho 
mRNA (Figure 1A) and membrane-bound Klotho mRNA (Figure 1B), we detected both at 
predicted amplicon lengths of 240 and 190 bp, respectively. DNA sequencing confirmed the 
transcripts to be normal Klotho mRNA coding for membrane-bound Klotho, with exon 3 and 
exon 4 being contiguous (corresponding to the lower band), and as alternative Klotho mRNA 
putatively coding for secreted Klotho protein, with exon 3 extended by 50 nucleotides of intronic 
sequence, creating an in-frame premature termination codon (TAG) (corresponding to the upper 
band).  
 
Inhibition of nonsense-mediated mRNA decay prevents degradation of alternative Klotho mRNA 
To assess whether alternative Klotho mRNA is subject to degradation by NMD, we inhibited 
protein translation in HK-2 cells using cycloheximide (CHX), since NMD is a translation-
dependent process, inhibited by protein synthesis inhibitors (33). In 6 hours, we observed a time-
dependent accumulation of alternative Klotho mRNA using RT-PCR/densitometry 
(alternative/membrane-bound Klotho mRNA ratio increase from 0.14±0.02 to 0.44±0.06, 
p<0.001) (Figure 2A, B, Supplemental Table 1) and qRT-PCR (alternative/membrane-bound 
Klotho mRNA expression level increase from 0.57±0.01 to 0.86±0.12, p=0.013) (Figure 2C, 
 6 
 
Supplemental Table 1). This CHX-induced increase suggests that alternative Klotho mRNA is an 
NMD target. To confirm these findings, we silenced the Upf1 gene (Supplemental Figure 1), 
which codes for NMD core factor UPF1, in HK-2 cells. After 120 hours, we observed an 
increase in alternative Klotho mRNA abundance as compared to scrambled siRNA-transfected 
controls, using RT-PCR/densitometry (ratios 0.24±0.02 versus 0.35±0.02 after 120 hours, 
p<0.001) (Figure 2D, E, Supplemental Table 2) and qRT-PCR (relative expression level 
0.57±0.07 versus 0.96±0.17, p=0.027) (Figure 2F, Supplemental Table 2). The lack of alternative 
Klotho mRNA accumulation at 48 h may indicate that UPF1 was not yet depleted. In short, 
inhibition of NMD induces accumulation of alternative Klotho mRNA, indicating that alternative 
Klotho mRNA is an NMD target transcript.  
 
RNA immunoprecipitation for up-frameshift protein 1 (UPF1) 
As UPF1 is not displaced by ribosomes from PTC-containing mRNAs, another method of 
identifying NMD targets is by RNA immunoprecipitation (RIP) for UPF1 and comparing the 
abundance of bound PTC transcripts to their non-PTC counterparts (34). In HK-2 lysate, 
alternative Klotho mRNA was bound to UPF1 more abundantly than membrane-bound Klotho 
mRNA, as compared to input lysate (Figure 3A) and detected by RT-PCR/densitometry (ratios 
0.25±0.13 versus 1.37±0.63, p=0.004) (Figure 3C) or by qRT-PCR (ratios 0.59±0.22 versus 
2.17±0.84, p=0.004) (Figure 3D). An IgG control did not co-immunoprecipitate mRNA or 
protein, while β-actin was only detected in the input lysate, indicating that UPF1 
immunoprecipitation was specific (Figure 3A,B; Supplemental Figure 2 for full Western blots of 
three independent UPF1 RIP experiments). The finding that enriching for UPF1 protein (Figure 
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3B) increases the abundance of alternative Klotho mRNA as compared to the membrane-bound 
Klotho mRNA also suggests that alternative Klotho mRNA is an NMD target. 
 
Polysome fractionation 
To determine whether translation of both transcripts occurs, we fractionated HK-2 lysates using a 
sucrose gradient. Based on the absorbance profile at OD254, we identified fractions enriched for 
single ribosomes or polysomes (Figure 4A). Densitometric quantification of Figure 4B is shown 
in Figure 4C, while Figure 4D depicts means of replication experiments, standardized to input 
values. Membrane-bound Klotho mRNA was associated with both ribosome and polysome 
fractions, indicative of active translation. Alternative Klotho mRNA, however, was most 
abundantly associated with single ribosomes and was depleted in polysome-enriched fractions 
(372±122% of input ratio in single ribosome fractions and 35±22% of input ratio in polysome 
fractions, p=0.009) (Figure 4B-D), indicating that the pioneer round of translation occurs, but 
active protein translation does not.  
 
RNA in situ hybridization 
Using an RNA-ISH probe specific for alternative Klotho mRNA, we demonstrated specific 
expression of alternative Klotho mRNA in HK-2 cells as compared to controls without probe 
(Figure 5A,B). We then assessed whether this transcript is detected in P bodies, the organelles 
where NMD transcripts are degraded by exoribonculeases and decapping enzymes. Using 
decapping enzyme 1a (Dcp1a) as P body marker (Figure 5C-F), we found that some P bodies co-
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localized with alternative Klotho mRNA ISH signal (Figure 5G-I). The lack of co-localization in 
other P bodies may be the consequence of mRNA degradation. It should also be noted that P 
bodies are to an extent a heterogeneous set of organelles and perhaps only a specific subset 
would be involved in the degradation of this transcript.  
 
Detection of soluble Klotho in vitro 
As established, the alternative Klotho mRNA is an NMD target and does not undergo protein 
translation, which suggests that the putative “secreted Klotho” protein would not be produced. 
We therefore assessed which soluble Klotho proteins we would find in a human in vitro cell 
culture model in which Klotho is naturally produced. To that end, we let HK-2 cells condition 
serum-free culture medium for 48 and 72 hours, after which we concentrated the culture medium 
and performed a Western blot for Klotho using KM2076, which detects the KL1 domain (in 
either the membrane-bound protein or in soluble Klotho proteins containing the KL1 domain). 
As shown in Figure 6, full-length soluble Klotho (130 kDa) is detected as the recombinant 
protein and in both HK-2 cell lysate and supernatant. The KL1 domain is detected at the 
expected height of about 70 kDa in the recombinant human Klotho sample. HK-2 cell 
supernatant did not exhibit immunoreactivity with any proteins of that size. As shown in 
independent experiments depicted in Figure 6 and Supplemental Figure 3, two smaller bands 
were consistently detected at 65 kDa and at 55 kDa, which were determined to be, respectively, 
(residual) albumin, and a likely immunoglobulin chain, due to immunoreactivity with the 





Dysregulation of relative Klotho mRNA abundance in renal disease  
To assess whether the previous findings have any clinical relevance, we investigated the relative 
abundance of both mRNA transcripts in human kidneys and noticed a lot of variation, with ratios 
ranging from 0.03±0.01 to 0.20±0.02, in addition to a possible correlation between less 
alternative Klotho mRNA (lower ratio) and less renal damage (Supplemental Figure 4). We 
therefore investigated healthy tissue adjacent to resected renal cell carcinoma (RCC) (N=12), 
biopsies from brain-dead and living kidney donors (N=21), chronic kidney disease (CKD) 
(N=28), and acute kidney injury (AKI) (N=18). Patient characteristics are reported in Table 1. 
The RCC-adjacent samples displayed a very low alternative/membrane-bound Klotho mRNA 
ratio (0.05±0.01), which was similar to kidney donors (0.05 [0.04-0.07]). A modest, but 
significant increase was observed in CKD samples (0.07±0.03, p=0.003) and a marked, 
significant increase was found in AKI samples (0.22±0.11, p<0.001) (random samples depicted 
in Figure 7A, quantification of all samples in Figure 7B). Furthermore, comparing Klotho protein 
expression between three kidneys with low and three kidneys with high Klotho mRNA ratios, we 
found lower Klotho protein expression in kidneys with a higher relative abundance of alternative 
Klotho mRNA transcript (Figure 7C). No difference was observed between living and brain-dead 
donor kidneys (Supplemental Figure 5). 
 
Dysregulation of relative Klotho mRNA abundance in vitro 
To assess whether the difference observed in patients constitutes a general damage response, we 
investigated different in vitro damage models to see whether an increase in the 
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alternative/membrane-bound Klotho mRNA ratio would be observed. Using heat shock (45 min 
at 43 °C) as a physical stressor, we noted an increase in ratio, 24 hours after heat shock compared 
to 1 hour before heat shock (0.19±0.02 versus 0.38±0.06, p=0.003) (Figure 8A, B). Using 
stimulation with H2O2 as an in vitro model for oxidative stress, we found an increase in ratio 
using 1 mM H2O2 (0.18±0.04 versus 0.39±0.01, p<0.001) (Figure 8C, D). Incubating with 
indoxyl sulfate (IS) for 48 hours as an in vitro model for uremia, the ratio was found to increase 
using 5 mM IS (0.19±0.03 versus 0.27±0.03, p=0.015) (Figure 8E, F). As a proof of principle, 
we also observed a shift in relative Klotho mRNA transcript abundance strongly favouring the 





The major findings of this study are the identification of the alternative Klotho mRNA transcript 
as a nonsense-mediated mRNA decay target and dysregulation of its splicing as a result of renal 
damage in vitro and in vivo.  
We have demonstrated that the PTC-containing alternative Klotho mRNA transcript accumulates 
upon inhibition of NMD, is enriched after immunoprecipitation for NMD core factor UPF1, and 
does not actively undergo protein translation. These findings indicate that alternative Klotho 
mRNA is an NMD target that does not translate to protein in the kidney. This has several 
implications. First of all, if alternative Klotho mRNA does not produce a protein, the concepts of 
secreted Klotho protein and the physiology of its secretion are in question. To our best 
knowledge, the human secreted Klotho protein has not yet been identified (13), nor did we detect 
it, so we posit that it may be best to consider kidney-derived secreted Klotho protein non-existent 
and the alternative mRNA transcript as an NMD target in human physiology.  
Secondly, in the absence of secreted Klotho, the proteins commonly designated as circulating or 
soluble Klotho are likely derived from cleaved membrane-bound Klotho only and proteolytic 
cleavage would gain relevance as the process generating circulating Klotho (13,14,35-37). In line 
with cleaved Klotho as sole contributor to circulating Klotho is an experiment performed by Hu 
et al., who show that inhibition of both α- and β-secretases for 48 hours in mice virtually depletes 
circulating Klotho (38).  
The question why Klotho gene splicing results in two transcripts of which one is continuously 
degraded, is not easily answered, but it can be placed in context. NMD is widely used to 
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compensate for the inaccuracy of splicing, since about a third of the total number of transcripts is 
estimated to contain a PTC (39). Furthermore, selective pressure for introns to produce PTCs in 
the event of intron retention may exist (40). Additionally, a process termed regulated 
unproductive splicing and translation (RUST) may fine-tune protein expression levels more 
precisely than occurs at the transcriptional level by producing nonsense transcripts (41).  
We have selected different approaches to substantiate the involvement of NMD in the fate of 
alternative Klotho mRNA beyond sequence-based prediction. It is challenging to study NMD in 
a physiological setting and most studies are performed by overexpressing PTC-containing 
mRNAs. The resultant high expression levels and, in turn, our constitutively low physiological 
alternative Klotho mRNA expression levels, are likely the reason behind comparatively modest 
effect sizes in our cycloheximide and UPF1 silencing experiments. While not impossible to 
perform our experiments with transfected Klotho plasmids with and without PTCs, it is 
challenging having to use the large, native 50 kb gene, since splicing is eliminated in cDNA 
translation. As expected, “secreted Klotho” cDNA leads to protein production for this reason 
(10,42,43), which is likely non-physiological, notwithstanding the biological effects of 
overexpressed “secreted Klotho”, essentially amounting to KL1 domain effects (3,44-50). 
Notably, the antibody we used to detect Klotho (KM2076) would detect the KL1 domain in any 
KL1-containing form of Klotho (13,51). Additionally, our choice to study naturally occurring 
PTC-containing mRNA makes our study more relevant for physiology and the non-PTC 
counterpart functions as internal control.  
On a related note, using a physiological cell system of Klotho production, we did not detect a 
truncated, KL1 domain-containing, secreted Klotho protein in HK-2 cell supernatant. While 
smaller proteins were detected, we were able to identify one band as detected by the secondary 
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antibody and the other band as residual bovine serum albumin, which could not be washed away. 
KM2076 has been shown before to have some affinity for albumin if abundantly present (52). 
While not detecting “secreted Klotho” is not conclusive evidence of non-existence and proving a 
negative is problematic on multiple levels, we think that the lines of evidence demonstrating that 
the alternative Klotho mRNA is not actively translated, undergoes NMD instead, and any 
hypothetical protein product could not be detected, strongly support our conclusion. One study 
by Massó et al., however, merits some further discussion, as they aimed to study the putative 
mouse “secreted klotho” protein by generating an antibody, K113, against the murine unique 
amino acid sequence (23). They detected a protein on Western blot that was expressed at a level 
in the brain 9-fold higher than in kidney. Adding to that, qRT-PCR data by Massó et al. indicate 
that in the brain, the membrane-bound klotho transcript is expressed at a level that was 78-fold 
higher compared to the alternative transcript. Since klotho is well-documented to be expressed at 
a much lower level in the brain compared to the kidney, these findings are difficult to interpret. 
We should also consider that the expression pattern for this antibody has not yet been studied, it 
has not been used for detecting the putative “secreted klotho” in blood or other extracellular 
compartments, nor has it been validated using Klotho-/- samples. A possible relationship between 
the alternative klotho transcript in mouse and the protein detected by K113 is therefore yet to be 
established, especially since previous studies using validated antibodies have not resulted in the 
detection of circulating “secreted Klotho” (13). 
As a technical note, given the relative variability in expression level of both Klotho mRNA 
transcripts, actual (membrane-bound) Klotho levels are variably overestimated, especially Klotho 
down-regulation in AKI. To circumvent indistinguishable amplification of both transcripts, 
primers flanking the exon 3–exon 4 boundary and a probe spanning that boundary are the best 
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tools for accurate human Klotho expression qRT-PCR analysis. While we slightly underestimate 
the relative abundance of alternative Klotho mRNA by employing a competitive RT-PCR, this is 
not an uncommon approach (40) and results were highly consistent and reproducible, while qRT-
PCR invariably yielded highly similar results, albeit with slightly more variation due to separate 
amplification reactions. 
Furthermore, an interesting finding in our study is that in both CKD and AKI, the relative 
abundance of alternative Klotho mRNA is increased. Because depletion of circulating Klotho 
levels is found after bilateral nephrectomy (38) and after kidney-specific deletion of Klotho (32), 
the kidney has been identified as principal contributor to systemic Klotho levels, adding to the 
relevance of our findings in renal cells and tissues. Caution, however, should be exercised in 
extrapolating our “secreted” Klotho results to other tissues. It is difficult to discriminate between 
dysfunction of NMD and dysregulation of splicing, two processes that are particularly 
intertwined. However, the down-regulation of membrane-bound Klotho mRNA relative to the 
increase in alternative Klotho mRNA suggests that at least a dysregulation in splicing is 
involved. This could essentially amount to down-regulation of membrane-bound Klotho protein. 
Further supporting this notion, we indeed found lower Klotho protein levels in kidneys with a 
relatively higher alternative Klotho mRNA abundance, although various other mechanisms, such 
as promoter hypermethylation, are likely to contribute as well. It is currently unclear why Klotho 
is rapidly down-regulated in renal disease while up-regulation would be protective (31), but we 
may have identified the existence of alternative Klotho mRNA and dysregulation of its splicing 
as possible mechanisms contributing to Klotho down-regulation, in addition to transcriptional 
regulation (16,53,54), epigenetic regulation (55-57), and miRNAs (58,59).  
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Moreover, identification of alternative Klotho mRNA as an NMD target may cast a different 
light on published studies. For example, Lu et al. find that ovarian carcinoma patients positive 
for alternative Klotho mRNA have a higher tumour grade (17), which is interesting in light of the 
generally accepted view of Klotho as a tumour suppressor (44,46,60,61), including in ovarian 
carcinoma (62,63). However, higher alternative Klotho expression levels may not implicate 
effects of Klotho protein in whichever form, and may even indicate dysregulated splicing or 
NMD dysfunction, which would lead to endoplasmic reticulum stress and may therefore reflect 
general cellular health.  
To conclude, we have shown that the human alternative Klotho mRNA is a target for nonsense-
mediated mRNA decay and does not undergo protein translation, indicating that the supposed 
kidney-derived “secreted Klotho” does not exist. Furthermore, in vitro and in vivo renal damage 
result in increased alternative Klotho mRNA and in decreased membrane-bound Klotho mRNA 
levels, likely due to dysregulated splicing, essentially constituting an additional mechanism that 
may contribute to down-regulation of Klotho in renal disease. Additional research is needed to 
elucidate the regulation of this process and for strategies aimed at improving Klotho gene 







HK-2 cells (kindly provided by Theo Borghuis, Division of Medical Biology, UMCG, 
Groningen) were cultured in growth medium consisting of low-glucose (1 g/L) DMEM (Lonza, 
Switzerland) supplied with 10% fetal calf serum (FCS), 1% 100 IE penicillin/100 µg 
streptomycin solution and 1% 200 mM L-glutamine solution. Human renal cortical tubular 
epithelial cells (RTECs) were isolated and cultured as previously described (64). Cells were 
incubated at 37 °C and 5% CO2. For cycloheximide experiments, cells were serum-starved for 24 
hours before medium was changed to growth medium supplied with 100 µg/mL cycloheximide 
(Sigma-Aldrich, USA) for 0, 2, 4, or 6 hours. Heat shock was performed at 43 °C for 45 min, 
using a water bath and continuous temperature monitoring, by submerging sealed culture plates. 
HK-2 cells were harvested before heat shock, 1 h after initiation of heat shock, and 24 h later. 
Oxidative stress was induced in vitro by adding 0 µM, 100 µM, 500 µM, 1 mM H2O2 (Merck, 
USA) in growth medium to HK-2 cells for 24 h. Indoxyl sulfate (I3875, Sigma-Aldrich) was 
used to stimulate cells for 48 or 96 h in concentrations of 0 µM, 200 µM, 1 mM, and 5 mM in 
serum-containing growth medium. All stimulation experiments were preceded by 24 h of serum 
starvation. To study the presence of Klotho in conditioned medium, T-75 flasks with HK-2 cells 
at subconfluence were washed with HBSS (Lonza), and incubated with serum-free culture 
medium for 48 or 72 hours, after which medium was collected and cells were lysed. Supernatants 






Silencer Select siRNAs against Upf1 (s11926; Ambion/Thermo Fisher Scientific, USA) or 
scrambled negative control siRNAs and lipofectamine RNAiMAX (Thermo Fisher Scientific) 
were mixed in Opti-MEM reduced serum medium (Gibco/Thermo Fisher Scientific), before 
transfection of HK-2 cells suspended in DMEM/10% FCS. The final siRNA concentration was 
10 nM. Cells were re-transfected after 72 hours. 
 
RT-PCR 
Cells and tissues were lysed in TRIzol, followed by RNA extraction using chloroform, 
precipitation with 2-propanol, washing in 70% ethanol and solubilizing in nuclease-free water. 
Synthesis of cDNA was performed using random hexamer primers and Superscript II. To 
investigate the relative abundance of the alternative and membrane-bound Klotho transcripts, 
PCR was performed using the following primers: a forward primer specific for exon 3 of the 
human Klotho gene (CTAAGCCAGGACAAGATG) and a reverse primer specific for exon 4 of 
the human Klotho gene (TCAGGTCGGTAAACTGAG) and a PCR program of 40 cycles of 30 s 
at 94 °C, 30 s at 59 °C and 30 s at 72 °C. PCR products were separated on a 2% agarose gel. 







Primer/probe sets were used specific for the membrane-bound Klotho mRNA (TaqMan assay 
Hs00935388_m1, Thermo Fisher Scientific) and for the alternative Klotho mRNA (forward: 
AACTACATTCAAGTAAGTCAGC, reverse: CAGAGTGGTATCTACTAGTG, probe: 5’-56-
FAM/TCAGCAGTC/ZEN/TCACCAAGCCCT/31ABkFQ-3’, IDT, USA). The following 
program was used on an ABI7900HT (Applied Biosystems, USA): 2 minutes at 50 °C, 10 
minutes at 95 °C, followed by 40 cycles of 15 seconds at 95 °C and 60 seconds at 60 °C. 
Relative expression levels were calculated using the 2(-ΔCt) method. TATA box-binding protein 
(TBP) was used as a normalization gene. 
 
DNA sequencing 
Bands were excised from 2% agarose gels under a UV light and DNA was extracted using the 
Zymoclean Gel DNA Recovery Kit (Zymo Research, USA). Briefly, agarose gel pieces were 
liquefied in ADB buffer at 54 °C, after which DNA was collected on a spin-column. DNA was 
washed on a column and eluted from the column, after which it was sequenced by LGC 
Genomics GmbH (Berlin, Germany). DNA sequences were analysed using the CLC Main 
Workbench (Qiagen, Germany). 
 
RNA immunoprecipitation (RIP) 
RIP was performed according to (25) with minor modifications. HK-2 cells from two confluent 
75 cm2 flasks were lysed for 20 min on ice, using 1.2 mL of 10 mMol Tris/10 mM NaCl//2 mM 
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EDTA/0.5% Triton X-100 (pH 7.5) supplied with Halt protease inhibitor cocktail (1861279. 
Thermo Fisher Scientific) and RiboLock RI RNase inhibitor (EO0381, Thermo Fisher 
Scientific), followed by centrifugation at 16,000 g for 15 min at 4 °C. Input samples (50 µl for 
protein, mixed with 50 µl 2x Laemmli samples buffer, and 100 µl for RNA isolation, treated 
with RiboLock RI RNase inhibitor and Turbo DNase (AM2238, Ambion) for 5 min at 37 °C) 
were set apart. The remainder of the lysate was rendered isotonic by correcting the sodium 
concentration and 500 µl was incubated with 7 µg rabbit anti-UPF1 antibody (03-191, Merck 
Millipore, USA) or 7 µg rabbit IgG for 90 min. Then, 64 µl of protein G Dynabeads (10004D, 
Thermo Fisher Scientific) were washed in wash buffer (150 mM NaCl/50 mM Tris/0.05% NP-
40, pH 7.5), lysis buffer, and then incubated for 1 h in lysis buffer with 1% bovine serum 
albumin (BSA) and 0.1% yeast tRNA (15401-011, Thermo Fisher Scienfitic). After washing 
twice with lysis buffer, 32 µl of beads were added to the lysates and were incubated for 90 
minutes at 4 °C. Beads were then isolated magnetically and were washed six times for 5 min in 1 
mL Net-2 buffer (150 mM NaCl/50 mM Tris/0.1% Triton X-100, pH 7.5) at 4 °C. One third of 
the beads was then mixed with 2x Laemmli sample buffer and two thirds were used for DNAse 
treatment and RNA isolation. The work-up of IgG fraction-associated RNA for cDNA synthesis 




Samples in 1x Laemmli buffer were heated for 5 min at 95 °C, followed by SDS-PAGE of 10 µl 
of input lysate or RIP samples on 8% polyacrylamide gels for 90 minutes at 100 V. Proteins were 
 20 
 
then transferred to a methanol-activated PVDF membrane at 100 V for 90 minutes. Ponceau 
staining was performed to assess protein transfer and sample quality. Membranes were blocked 
in 5% non-fat dried milk in TBST for 30 min at RT. Incubation with goat anti-UPF1 (1:200; 
A300-038A, Bethyl Laboratories, USA) was performed overnight in 5% non-fat dried milk in 
tris-buffered saline/0.05% tween-20 (TBST) at 4 °C. After washing in TBST, membranes were 
incubated with rabbit anti-goat-HRP (1:1500; P0449, Dako) for 1 h at RT and washed with 
TBST. Β-actin (mouse anti-β-actin-HRP, sc-47778, Santa Cruz Biotechnology, USA) was used 
as a loading control and as a control for RIP fraction purity. Western blotting for Klotho was 
performed using monoclonal antibody KM2076 (TransGenic Inc., Japan) 1:500 and rabbit anti-
rat-HRP (P0450, Dako), on nitrocellulose, using 10 µl of concentrated supernatant sample, 40 µg 
of HK-2 cell lysate, and 5 ng of recombinant human Klotho (R&D Systems). Blots were re-
probed with anti-albumin (AHP102, Serotec, USA) and rabbit anti-sheep-HRP (P0163, Dako) 
which were kindly provided by Fransien van Dijk, Dept. Pharmacokinetics, Toxicology and 
Targeting — Groningen Research Institute of Pharmacy, UMCG, Groningen). Imaging was 
performed using chemiluminescence (SuperSignal West Femto Chemiluminescent Substrate or 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and a ChemiDoc 




Formalin-fixed, paraffin-embedded renal tissue sections (4 µm) were deparaffinised and re-
hydrated. Endogenous peroxidase activity was blocked, and antigens retrieved by boiling 
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sections for 15 min in 1 mM EDTA (pH 8). Slides were rinsed with PBS prior to incubation with 
rat-anti-Klotho (clone KM2076, TransGenic Inc., Japan) dilution 1:100 in 5% BSA solution for 1 
hour at RT, followed by incubation with secondary antibody rabbit anti-rat HRP (1:300, Vector 
Labs, cat no. AI-4001) for 45 minutes. Sections were then incubated with an anti-rabbit and 
multiple HRP-conjugated polymer (Dako) for 30 minutes. Peroxidase activity was detected with 
3-amino-9-ethylcarbazole (AEC, Dako). Slides were counterstained with Mayer’s hematoxylin 
(Merck, Germany). All slides were scanned using a Hamamatsu Nanozoomer 2.0HT 
(Hamamatsu Photonics, Hamamatsu, Japan) and representative images were selected. 
 
Polysome fractionation 
Polysome fractionation was performed according to (65) with minor modifications. Sucrose 
gradients were prepared on the day before fractionation by layering 7%, 17%, 27%, 37%, and 
47% sucrose solutions in lysis buffer (20 mM HEPES, 15 mM MgCl2, 200 mM KCl, and 100 
µg/mL cycloheximide) in 38.5 mL Ultra-Clear centrifuge tubes (344058, Beckman-Coulter, 
USA). Gradients were stored overnight at 4 °C to become continuous. HK-2 cells in six 
confluent 75 cm2 culture flasks were washed with PBS and incubated with cycloheximide (100 
µg/mL) at 37 °C for 15 min to freeze the ribosomes on their mRNA strands. Cells were then 
washed with PBS, placed on ice, and lysed using 1 mL lysis buffer consisting of 20 mM HEPES, 
15 mM MgCl2, 200 mM KCl, 1% Triton X-100, and 100 µg/mL cycloheximide. Cells were 
collected using a scraper, were mechanically disrupted by pipetting, and were centrifuged at 
14,000 g for 5 min at 4 °C. Supernatants were then pipetted onto the sucrose gradients, which 
were placed in a swinging bucket SureSpin 630 rotor and were centrifuged for 4 h at 23,000 g in 
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a Sorvall Discovery 90SE ultracentrifuge (Hitachi, Japan). Fractions of 1 mL were then collected 
and the absorbance at 254 nm was measured on the NanoDrop (Thermo Fisher Scientific). RNA 
was isolated from fractions using TRIzol and cDNA was synthesized from fractions with 
sufficient RNA content, followed by PCR on single ribosome- and polysome-enriched fractions. 
 
RNA in situ hybridization 
HK-2 cells were grown in Lab-Tek chamber slides (Thermo Fisher Scientific) and fixed using 
4% paraformaldehyde/5% acetic acid in PBS for 15 min. Cells were washed with PBS and 
incubated with rabbit anti-Dcp1a-A488 (1:100 Ab208275, Abcam, UK) for 1 h, after which 
imaging was performed on a Zeiss AxioObserver Z1 microscope equipped with TissueFAXS 
Image Analysis Software (TissueGnostics, Austria). Cells were then rinsed in PBS and treated 
with 0.1% pepsin/10 mM HCl for 1 min at 37 °C. Cells were then dehydrated and incubated with 
40 nM probe specific for the alternative Klotho mRNA 
(/5DigN/AGTGGTATCTACTAGTGATAGG/3Dig_N, Exiqon, Denmark) in 50% 
formamide/2xSSC/10% dextran sulfate/PBS. The probes were denatured at 80 °C for 2 min and 
then hybridized for 30 minutes at 54 °C on a ThermoBrite (Abbott, USA), after which slides 
were rinsed in 0.1% Tween-20/2xSSC and 3 times with 0.1xSSC at 65 °C. Cells were then 
incubated for 2x 5 min at RT in 0.15 M NaCl/0.1 M maleic acid (pH 7.5), followed by 15 min at 
37 °C in 1% blocking reagent (11096176, Roche, Switzerland) and 2% normal rabbit serum in 
0.15 M NaCl/0.1 M maleic acid, after which cells were incubated with the same buffer supplied 
with mouse anti-DIG antibody (1:2000; 11333062910, Roche) for 1 h at 37 °C. Cells were then 
incubated with rabbit anti-mouse (1:20; Z0259, Dako) for 30 min and with alkaline phosphatase-
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conjugated anti-alkaline phosphatase (1:50; D0651, Dako) for 30 min, followed by development 
of the chromogenic reaction using NBT, BCIP, and levamisole (Roche) overnight. Imaging was 
performed on a NanoZoomer 2.0HT (Hamamatsu, Japan).  
 
Statistical analysis 
Data were tested for normality using the Shapiro-Wilk test. Normally distributed data were 
reported as mean ± standard deviation (SD) and non-normally distributed data were reported as 
median [interquartile range], unless stated otherwise. Depending on the distribution, differences 
between groups were assessed by a one-sided Students t test or ANOVA, or by Mann-Whitney U 
or Kruskal-Wallis test. These tests were followed by Bonferroni’s or Dunn’s post-hoc test, 
respectively, to correct for multiple comparisons. A p value < 0.05 was considered significant. 
For statistical analysis, SPSS version 18.0.3 (IBM, USA) or GraphPad Prism 5.0 (GraphPad 
Software, USA) was used. 
 
Study approval and use of human tissue 
Post-mortem kidney biopsies were performed in 18 patients with sepsis and renal failure (66). 
Adult patients who died of sepsis in the ICU were included in the study. Control patients 
underwent total nephrectomy as a result of renal cell carcinoma. Exclusion criteria were pre-
existing chronic kidney disease, active autoimmune disorder with renal involvement, and 
treatment with immune-suppressive medication. For all patients, the next-of-kin was given an 
oral and written explanation about the study and written informed consent was taken if 
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permission was given. The Medical Ethics Review Committee (METC) of the University 
Medical Center Groningen (UMCG) reviewed and approved this study protocol (METc 
2011/372, Protocol ID 2011.AKI). Kidney biopsies were taken within 35 minutes postmortem. 
The patient was placed in prone position and the kidney was located by ultrasound. The biopsy 
device (Tru Core2 Biopsy Instrument, Angiotech, 14 Ga×20 cm, Ref. 763114200x, USA) was 
introduced through a small skin incision and multiple kidney cortex biopsies were taken under 
ultrasound guidance.  
For donor kidney biopsies, after informed consent was obtained from the patient or on his/her 
behalf from relatives, biopsies were taken before the start of cold ischemia. For RCC-adjacent 
renal tissue harvesting, the kidney was carefully inspected by the surgeon after nephrectomy and 
kidney cortex biopsies harvested distant from the renal cancer lesion. All kidney biopsies were 
fixed in 10% formalin and afterwards embedded in paraffin. Additionally material was snap 
frozen in liquid nitrogen and stored at -80 ºC. Chronic kidney disease biopsies (leftover after 
completion of diagnostic procedures) were similarly used in accordance with the Dutch law on 
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Figure 1. Identification of human Klotho mRNA transcripts by RT-PCR and DNA 
sequencing. (A) The alternative Klotho mRNA transcript is detected in human kidney, primary 
renal tubular epithelial cells, and in the human HK-2 renal cell line. PCR using primers spanning 
exons 3 and 4 (indicated by closed purple arrows) yields two PCR products. DNA sequencing 
confirms that the 240 bp PCR product corresponds to the alternative Klotho mRNA, which 
contains a 50 bp insertion (purple) between exon 3 (green) and 4 (orange), yielding a premature 
TAG stop codon (underlined in red). The alternative Klotho exons are depicted schematically, 
including the intronic sequence between exons 3 and 4 (green). (Note: nucleotide 145 in this 
sequence has similarly low signals for G and C, but is a G according to published sequences.) 
(B) The membrane-bound Klotho mRNA transcript is detected in human kidney, primary renal 
tubular epithelial cells, and in the human HK-2 renal cell line. PCR using primers spanning 
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exons 3 and 4 (indicated by closed purple arrows) yields two PCR products. DNA sequencing 
confirms that the 190 bp PCR product corresponds to the membrane-bound Klotho mRNA, 
which does not contain the 50 bp insertion between exon 3 and 4. The membrane-bound Klotho 






Figure 2. Blocking nonsense-mediated mRNA decay, using cycloheximide or by silencing 
UPF1, results in the accumulation of the alternative Klotho mRNA transcript in HK-2 cells.  
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(A) RT-PCR for the two Klotho transcripts in HK-2 cells incubated with 100 µg/ml 
cycloheximide for 0, 2, 4, or 6 h, showing accumulation of the alternative Klotho transcript. (B) 
Densitometric quantification of (A), expressed as the ratio of the alternative and membrane-
bound Klotho mRNAs (values are provided in Supplemental Table 1). (C) qRT-PCR analysis for 
both Klotho transcripts, using as ΔCt = Ct(alternative Klotho transcript) – Ct(membrane-bound 
Klotho transcript), which confirms the RT-PCR results. (D) RT-PCR for the two Klotho 
transcripts in HK-2 cells after Upf1 or scrambled siRNA transfection for 48 or 120 h, showing 
accumulation of the alternative Klotho transcript after 120 h. (E) Densitometric quantification of 
(D), expressed as the ratio of the alternative and membrane-bound Klotho mRNAs (values are 
provided in Supplemental Table 2). (F) qRT-PCR analysis for both Klotho transcripts, using as 
ΔCt = Ct(alternative Klotho transcript) – Ct(membrane-bound Klotho transcript), confirms the 
RT-PCR results. * p < 0.05, ** p < 0.01, *** p < 0.001, as tested by ANOVA with post-hoc 
Bonferroni correction. All individual data points represent means of three independent 






Figure 3. RNA immunoprecipitation of HK-2 cell lysate reveals enrichment of the 
alternative Klotho mRNA associated with UPF1. (A) RT-PCR analysis for both Klotho 
transcripts in HK-2 cell lysate (input), after immunoprecipitation for UPF1, and after 
immunoprecipitation with rabbit IgG, showing enrichment for the alternative Klotho mRNA in 
UPF1-associated RNA. (B) Western blot analysis for UPF1 and β-actin in HK-2 cell lysate and 
after immunoprecipitation with rabbit anti-UPF1 or rabbit IgG, showing enrichment for UPF1 
and depletion of other proteins, as indicated by absence of β-actin in IP fractions. (C) 
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Densitometric quantification of (A), expressed as the ratio of the alternative and membrane-
bound Klotho mRNAs. (D) qRT-PCR analysis for both Klotho transcripts, using as ΔCt = 
Ct(alternative Klotho transcript) – Ct(membrane-bound Klotho transcript), confirms the RT-PCR 
results. ** p < 0.01, as tested by Student’s t test. All individual data points represent values from 






Figure 4. Polysome fractionation of HK-2 cell lysate on sucrose gradients reveals 
enrichment of the alternative Klotho mRNA associated with single ribosomes and depletion 
in polysome-associated fractions. (A) Representative absorbance spectrum of sucrose gradient 
fractions at 254 nm allows for identification of fractions enriched for free material, single 
ribosome subunits, single ribosomes, and polysomes. (B) RT-PCR analysis for both Klotho 
transcripts in non-fractionated HK-2 cell lysate, in single ribosome-associated fractions, and in 
polysome-associated fractions, showing enrichment for the alternative Klotho mRNA on single 
ribosomes and depletion in polysomes. (C) Densitometric quantification of the experiment in 
(B), expressed as the ratio of the alternative and membrane-bound Klotho mRNAs. Individual 
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data points refer to individual fractions (with mean ± SD). (D) Overall densitometric 
quantification of three replicate experiments, expressed as the ratio of the alternative and 
membrane-bound Klotho mRNAs, standardized to the non-fractionated lysate. ** p < 0.01, *** p 
< 0.001, as tested by Student’s t test. Individual data points represent means of independent 






Figure 5. RNA in situ hybdridization for the alternative Klotho mRNA transcript in HK-2 
cells reveals co-localization with some P bodies. (A) RNA in situ hybridization for the 
alternative Klotho mRNA transcript indicates expression in HK-2 cells. (B) Control cells 
hybridized without probe. (C) Immunofluorescence for Dcp1a identifies P bodies in HK-2 cells, 
(D) merged with bright-field image. (E) Immunofluorescence without primary antibody, (F) 
merged with bright-field image. (G) Immunofluorescence for Dcp1a in HK-2 cells, (H) merged 
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with bright-field image. (I) RNA-ISH reveals that some P bodies in the HK-2 cells in (G, H) co-
localize with the signal for the alternative Klotho mRNA transcript (arrows). Images depicted in 
panels A, B and I were digitally contrast-enhanced to 150% in Microsoft Powerpoint. Original 





Figure 6. A putative “secreted Klotho” protein is not detected in HK-2 cell supernatant. (A) 
Western blot for Klotho on HK-2 cell lysate, 48 h-conditioned supernatant, and recombinant 
human (Rh) Klotho. Note the 130 kDa bands corresponding to full-length Klotho in HK-2 cells 
and in supernatant, similar to 130 kDa positive control recombinant Klotho. While a 70 kDa KL1 
band was detected in the positive control, no such band was detected in HK-2 cell supernatant. 
Note that the relative densities of the recombinant protein and KL1 fragment are unrelated to the 
expected secondary cleavage of 130 kDa soluble Klotho generated by HK-2 cells. Smaller bands 
were determined to correspond to albumin and a likely immunoglobulin chain, as detailed in 
Supplemental Figure 3. (B) Ponceau S protein staining showing a prominent band at 65 kDa in 
HK-2 supernatant, corresponding to albumin, which is likely residual bovine serum albumin 






Figure 7. The relative abundance of the Klotho gene transcripts is dysregulated in vivo in 
renal disease. (A) RT-PCR analysis of healthy renal cortices and acute kidney injury samples 
for both Klotho transcripts. (B) Densitometric quantification of renal cell carcinoma (RCC)-
adjacent healthy renal cortices (N = 12), donor kidney biopsies (N = 20), biopsies from kidneys 
afflicted with chronic kidney disease (CKD) (N = 28), and biopsies from kidneys suffering from 
acute kidney injury (AKI) (N = 18). (C) Immunohistochemistry for Klotho on kidneys with high 
alternative / membrane-bound Klotho mRNA ratios (N = 3) and kidneys with low alternative / 
membrane-bound Klotho mRNA ratios (N = 3) reveals lower Klotho protein expression in the 
kidneys with a relatively higher alternative Klotho mRNA abundance. Original magnifications: 
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200×.  * p < 0.05, ** p < 0.01, *** p < 0.001, as tested by Kruskal-Wallis test with Dunn’s post-




Figure 8. The relative abundance of the Klotho gene transcripts is dysregulated in vitro 
after different stimuli. (A) RT-PCR analysis for both Klotho transcripts after application of a 
heat shock as a physical stressor (45 min at 43 °C) to HK-2 cells, that were lysed before the heat 
shock (t = -1 h), after the heat shock (t = 0 h), or 24 h later. (B) Densitometric quantification of 
(A), showing an increase in the alternative / membrane-bound Klotho mRNA ratio after 24 h. (C) 
RT-PCR analysis for both Klotho transcripts after stimulation with different concentrations of 
H2O2 for 24 h, to induce oxidative stress in HK-2 cells. (D) Densitometric quantification of (C), 
showing an increase in the alternative / membrane-bound Klotho mRNA ratio after stimulation. 
(E) RT-PCR analysis for both Klotho transcripts after stimulation of HK-2 cells with different 
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concentrations of indoxyl sulfate for 48 h, as a model for uremia. (F) Densitometric 
quantification of (E), showing a dose-dependent increase in the alternative / membrane-bound 
Klotho mRNA ratio after stimulation. Depicted are individual data points representing mean of 
three independent experiments, performed in triplicate (plotted with mean ± SD). * p < 0.05, ** 
p < 0.01, *** p < 0.001, as tested by ANOVA with Bonferroni’s post-hoc test. 
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(N = 12) 
Donor 
biopsies  





(N = 21) 
Acute kidney 
injury  
(N = 18) 
Age (years; mean [range]) 59 [20-79] 43 [9-67] 54 [20-77] 69 [40-83] 
Sex (M:F) 5:7 10:10 20:8 10:8 
Pathology 




- IgA nephropathy 
- Sepsis 
- RCC (renal cell 
carcinoma) 
- Brain death 



































 Supplemental figure 1. qRT-PCR control of RNA interference efficacy of Upf1 in HK-2 
cells 48 h and 120 h after transfection. Individual data points represent means from 
independent experiments, plotted with means ± SD. 
 
  




Supplemental figure 3. Characterization of bands detected on Western blot in HK-2 cell 
supernatant. (A) Western blot for Klotho (using KM2076) on HK-2 cell supernatant (48 h 
conditioning; left lane) and recombinant human Klotho (right lane), showing a pattern similar 
to Figure 6A. (B) Secondary antibody control for (A), showing that the ~50 kDa band is 
reactive with polyclonal rabbit anti-rat antibodies, making it likely an immunoglobulin heavy 
chain. (C) Clarification of samples and ladder protein sizes for all panels. (D) Western blot for 
Klotho (using KM2076) on HK-2 cell supernatant (72 h conditioning) and recombinant 
human Klotho, showing a pattern similar to Figure 6A. (E) Re-probing of (D) for albumin, 
identifying the 65 kDa band in (D) as albumin. (F) Ponceau S protein staining for (D), 
depicting a prominent band at 65 kDa, identified as residual albumin in (E). 
 
Supplemental figure 4. Klotho gene splicing is highly variable between different human 
kidneys and there may be a link between renal damage and dysregulation of Klotho 
gene splicing.  (A) RT-PCR of the membrane-bound and alternative Klotho mRNA 
transcripts in random samples of healthy and acute kidney injury human kidney samples. (B) 
Densitometric quantification of three independent gene expression analyses, plotted as 
individual data points and depicted with mean ± SD. The healthiest kidneys (green bars) 
appear to be the kidneys with the lowest relative alternative Klotho mRNA expression. 
 
  
 Supplemental figure 5. Densitometric quantification of RT-PCR analysis for both Klotho 
transcripts on biopsies from living kidney donors (N = 9) and brain-dead kidney donors 
(N = 10), showing no difference between these groups. Individual data points are plotted 
with mean ± SD. 
 
  
Supplemental figure 6. Proof of principle that the relative abundance of the Klotho gene 
transcripts can be highly dysregulated in vitro. RT-PCR analysis for both Klotho 
transcripts after stimulation of HK-2 cells with different concentrations of indoxyl sulfate (IS) 
for 96 h, shows a marked shift towards the alternative Klotho mRNA using 5 mM.
Supplemental Table 1. Densitometric values and qPCR data of the example experiments depicted in Figure 2A-C. 
 
   
  T = 0 h T = 2 h T = 4 h T = 6 h 
Measurement Sample 1 2 3 1 2 3 1 2 3 1 2 3 
Densitometry              
Alternative Klotho band  1.00 1.13 1.03 1.01 1.12 1.08 1.55 1.53 1.58 1.71 1.90 1.76 
Membrane-bound Klotho band  5.94 6.08 6.87 5.50 5.48 5.00 4.46 4.74 5.29 4.22 3.81 3.63 
Ratio  0.17 0.19 0.15 0.18 0.21 0.22 0.35 0.32 0.30 0.41 0.50 0.49 
              
qPCR              
ΔCt(Ct(alternative Klotho) - Ct(membrane-
bound Klotho) 
 0.79 0.75 0.82 0.54 0.85 0.79 0.43 0.74 0.50 0.22 0.26 0.26 
2(-ΔCt)  0.58 0.59 0.57 0.69 0.56 0.58 0.74 0.60 0.71 0.86 0.84 0.84 
Supplemental Table 2. Densitometric values and qPCR data of the example experiments depicted in Figure 2D-F. 
 
  
  Scrambled 48 h Scrambled 120 h UPF1 48 h UPF1 120 h 
Measurement Sample 1 2 3 1 2 3 1 2 3 1 2 3 
Densitometry              
Alternative Klotho band  1.00 1.06 1.03 1.12 1.18 1.15 1.15 1.19 1.13 1.59 2.20 1.65 
Membrane-bound Klotho band  5.39 5.11 4.89 4.65 4.82 4.98 5.39 5.60 5.11 4.80 5.82 4.76 
Ratio  0.19 0.21 0.21 0.24 0.25 0.23 0.21 0.21 0.22 0.33 0.37 0.35 
              
qPCR              
ΔCt(Ct(alternative Klotho) - Ct(membrane-
bound Klotho) 
 0.45 1.15 0.75 0.53 0.48 0.84 0.80 1.09 0.96 0.78 -0.28 0.53 
2(-ΔCt)  0.73 0.45 0.59 0.69 0.72 0.56 0.58 0.47 0.51 0.58 1.21 0.69 
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